期刊文献+

PTEN表达下降对乳腺癌细胞生物学能力的影响 被引量:1

Influence of PTEN decent on biological ability of breast cancer cell
下载PDF
导出
摘要 目的:探讨PTEN基因在乳腺癌细胞中的表达及对其生物学特性的影响。方法:采用脂质体介导法将PTEN-shRNA转入表达PTEN的M231乳腺癌细胞中,构建PTEN基因沉默的细胞株M231-1548和M231-3001,检测PTEN基因沉默后M231乳腺癌细胞株黏附、转移及增殖能力的改变。结果:转染后M231-1548和M231-3001乳腺癌细胞PTEN蛋白表达量明显减少,其黏附能力明显下降,而迁移、侵袭能力及在三维培养中形成克隆的能力增强。结论:PTEN基因可以促进细胞黏附,抑制细胞增生、迁移和侵袭,对癌细胞具有抑制作用。PTEN基因的缺失可以作为评价乳腺癌患者的进展、转移等预后的指标之一。 Objective: To research the expression of PTEN and its influence on biological ability in breast cancer cell in vivo. Methods: PTEN-shRNA plasmid was transtected into M231 breast cancer cells to knock down the expression of PTEN. The changes of PTEN expression, proliferation, adhesion and metastasis of PTEN knocked down cell were tested by western-blot, colony formation, adhesion and invasion assay. Results: PTEN-shRNA was successfully transfected into M231 cells and it inhibited PTEN expression efficiently.The capabilities of colony formation, migration and invasion of transfected cell were much greater than those of the controlling cell line. But the transfected cells were more difficulty in adhesion than the scrambled ones. Conclusion: PTEN genecan enhance the adhesion, but restrict the proliferation, migration of breast cancer cells in some degree, so that inhibit the development of the breast cancer. PTEN loss can be a prognostic factors for the patients with breast cancer.
出处 《中国现代普通外科进展》 CAS 2010年第1期16-19,共4页 Chinese Journal of Current Advances in General Surgery
关键词 磷酸酶和张力蛋白同源缺失基因 乳腺肿瘤 肿瘤转移 Phosphatase and tensin homology deleted onchromosome ·Breast neoplasms· Metastasis
  • 相关文献

参考文献11

  • 1Li J,Yen C,Liaw D,et al.PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast,and prostate cancer[J].Science,1997,275(5308):1943-1947.
  • 2Depowski PL,Rosenthal SI,Ross JS.Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer cells[J].Mod Pathol,2001,14(7):672-676.
  • 3Leonardo S,Arkaitz C,Pier PP.Tenets of PTEN tumor suppression[J].Cell,2008,133(3):403-414.
  • 4Dourdin N,Schade B,Lesurf R,et al.Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis[J].Cancer Res,2008,68(7):2122-2131.
  • 5Leslie NR,Maccario H,Spinelli L.The significance of PTEN's protein phosphatase activity[J].Adv Enzyme Regul,2009,49:190-196.
  • 6Lu Y,Lin YZ,LaPushin R,et al.The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells[J].Oncogene,1999,18(50):7034-7045.
  • 7Carmen BA,Oliver R,Juan FML,et al.PTEN,more than the AKT pathway[J].Carcinogenesis,2007,28(7):1379-1386.
  • 8Gradishar WJ.The future of breast cancer:the role of prognostic factors[J].Breast Cancer Res Treat,2005,89(1):17-26.
  • 9Nagata Y,Lan KH,Zhou X,et al.PTEN activation contributes to tumor inhibition by trastuzumab,and loss of PTEN predicts trastuzumab resistance in patients[J].Cancer Cell,2004,6(2):117-127.
  • 10肖鸣,王雅杰.携带PTEN基因重组腺病毒对群司珠单抗耐药乳腺癌细胞的逆转作用[J].中国肿瘤生物治疗杂志,2008,15(5):433-439. 被引量:2

二级参考文献17

  • 1Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors [J].Breast Cancer Res Treat, 2005, 91(2) : 187-201.
  • 2Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptininduced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action[J].Cancer Res, 2002, 62(14) : 4132-4141.
  • 3Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment[J]. N Engl J Med, 2004, 351 (22) : 2337-2338.
  • 4Fujita T, Doihara H, Washio K, et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumabinduced growth inhibition in trastuzumab-resistant cells[ J ]. Anticancer Drugs, 2006, 17(4) : 455-462.
  • 5Lohrish C, PiccartM. An overview of HER2 [ J]. Semin Oncol, 2001,28(6 Suppl 18) : 3-11.
  • 6Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications [ J]. Ann N Y Acad Sci, 2005, 1059 : 70-75.
  • 7Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer[J]. Nat Clin Pract Oncol, 2006, 3(5) : 269-280.
  • 8Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line [ J ]. Cancer Res, 2005, 65(2) : 473-482.
  • 9Wang SE, Narasanna A, Perez-Torres M,et al. HER2 kinase do- main mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors[J]. Cancer Cell, 2006, 10(1) : 25-38.
  • 10Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3- kinase signaling network: implications for human breast cancer [J]. Oncogene, 2007, 26(9) : 1338-1345.

共引文献1

同被引文献14

  • 1Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phos- phatase gene mutated in human brain, breast, and prostate cancer[J]. Science, 1997,275(5308):1943-1947.
  • 2Salmena L, Carracedo A, Pandolfi PP.Tenets of PTEN Tumor Sup- pression[J]. Cell, 2008,133 (3):403-414.
  • 3Tanja Tamguney, David Stokoe. New insights into PTEN [J]. J Cell Sei, 2007,20:4071-4079.
  • 4Pandolfi PP. Breast cancer--loss of PTEN predicts resistance to treatment[J]. N Engl J Med, 2004,351 (22):2337-2338.
  • 5Dave B, Migliaccio I, Gutierrez MC, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers[J]. J Clin Oncol, 2011,29(2):166-173.
  • 6Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases [J]. Clin Ther, 2008,30(8):1426-1447.
  • 7Catherine Oakman, Malta Pestrin, Elena Zafarana, et al. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer[J]. Cancer Manag Res, 2010,2:13-25.
  • 8Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases[J]. Annu Rev Cell Dev Biol, 1997,13:513-609.
  • 9Wheeler DL, lida M, Dunn EF. The role of Src in solid tumors[J]. Oncologist, 2009,14(7 ):667-678.
  • 10Belsehes-Jablonski AP, Biseardi JS, Peavy DR, et al. Src family kinases and HER2 interactions in human breast cancer c;ell growth and survival[J]. Oncogene, 2001,20 ( 12 ): 1465-1475.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部